# YL211

Source: https://onco.cc/drugs/yl211/  
OnCo record `yl211` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

YL211 is an experimental antibody-drug conjugate aimed at c-MET, a protein on some solid tumours. MediLink Therapeutics licensed worldwide rights to Roche in January 2024, and it is in a first phase 1 trial.

## Summary

YL211 is an antibody-drug conjugate that targets c-MET (mesenchymal-epithelial transition factor) and uses MediLink Therapeutics' TMALIN conjugate platform. MediLink and Roche announced a worldwide collaboration and licence on 2 January 2024, with USD 50 million in upfront and near-term payments and a total deal value nearing USD 1 billion; MediLink was to run the first phase 1 trial with Roche's China Innovation Center before Roche took over global development. That phase 1 trial (NCT06384352), sponsored by MediLink with Hoffmann-La Roche as collaborator, started in May 2024 in advanced solid tumours and includes parts combining YL211 with pembrolizumab in non-squamous non-small cell lung cancer. The payload chemistry is not stated in the sources read. No results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; deal-asset
- Modality: Antibody-drug conjugate (c-MET)
- Mechanism: An antibody that recognises c-MET, a growth-signal receptor on some cancer cells, carries a drug payload into those cells using MediLink's TMALIN conjugate technology. The payload is not named in the sources read.

## Sources

- MediLink and Roche licence announcement, 2 January 2024 (1stOncology copy): https://1stoncology.com/blog/?p=92748
- ClinicalTrials.gov: YL211 phase 1 (NCT06384352): https://clinicaltrials.gov/study/NCT06384352

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [MET](https://onco.cc/targets/met/)
- companies: [MediLink Therapeutics](https://onco.cc/companies/medilink/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- trials: [Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06384352/)

---
JSON: https://onco.cc/api/v1/entities/yl211.json